---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040973"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:02:38.457635+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated

## Summary
- Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.
- Cash, cash equivalents, and marketable securities of $181.0M as of June 30, 2023; funds operations to early 2026.
- Positive 36-week Phase 2b ORIGIN results: significant proteinuria reduction and eGFR stabilization.
- Pivotal Phase 3 ORIGIN 3 trial for IgA nephropathy initiated in June 2023.
- Preliminary ORIGIN 3 data expected in first half of 2025; additional Phase 2b data in H2 2023 and 2024.

## SEC filing metadata
- accession: 0000950170-23-040973
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/0000950170-23-040973-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/vera-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040973
- JSON: https://secwatch.observer/filing/0000950170-23-040973.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040973.txt

## Key facts
- Earnings Releases
  Vera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $20.2 million, or $0.46 per share, EPS $0.46 per share.
  - Period: the second quarter ended June 30, 2023
  - Net income: a net loss of $20.2 million, or $0.46 per share
  - EPS: $0.46 per share
  - Result: reported results
  source text: For the quarter ended June 30, 2023, the company reported a net loss of $20.2 million, or $0.46 per share, compared to a net loss of $14.9 million, or $0.55 per share, for the same period last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831828/000095017023040973/0000950170-23-040973-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.